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Abstract
Background: Bone remodelling is dependent on the balance between bone resorbing osteoclasts
and bone forming osteoblasts. We have shown previously that osteoclasts contain gap-junctional
protein connexin-43 and that a commonly used gap-junctional inhibitor, heptanol, can inhibit
osteoclastic bone resorption. Since heptanol may also have some unspecific effect unrelated to gap-
junctional inhibition we wanted to test the importance of gap-junctional communication to
osteoclasts using a more specific inhibitor.
Methods: A synthetic connexin-mimetic peptide, Gap 27, was used to evaluate the contribution
of gap-junctional communication to osteoclastic bone resorption. We utilised the well-
characterised pit-formation assay to study the effects of the specific gap-junctional inhibitor to the
survival and activity of osteoclasts.
Results: Gap 27 caused a remarked decrease in the number of both TRAP-positive mononuclear
and multinucleated rat osteoclasts cultured on bovine bone slices. The decrease in the cell survival
seemed to be restricted to TRAP-positive cells, whereas the other cells of the culture model
seemed unaffected. The activity of the remaining osteoclasts was found to be diminished by
measuring the percentage of osteoclasts with actin rings of all TRAP-positive cells. In addition, the
resorbed area in the treated cultures was greatly diminished.
Conclusions: On the basis of these results we conclude that gap-junctional communication is
essential for the action of bone resorbing osteoclasts and for proper remodelling for bone.
Background
A series of complex and co-ordinated events is required
for bone remodelling [1,2]. Osteoblasts, osteocytes and
osteoclasts communicate with each other resulting in the
elaborate balance of bone formation and resorption.
Gap-junctional communication is well studied in the
communication between neighbouring osteoblasts and
between osteoblasts and osteocytes [3–8], but only little
is known about the communication between osteoclasts
and other bone cells. Gap-junctional protein, Connexin
43 (Cx43), has been identified between osteoclasts and
overlying or neighbouring mononuclear cells [9–12]. We
have recently demonstrated that bone-resorbing osteo-
clasts also contain gap-junctional proteins and that the
blocking of gap junctions by heptanol inhibits bone re-
sorption in vitro[12].
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in the resorption activity of osteoclasts, utilising the well-
characterised pit-formation assay. Gap 27 possesses con-
served sequence homology to a portion of the second ex-
tracellular loop leading into the fourth transmembrane
connexin segment (amino acid sequence SRPTEKTIFII)
[13]. The Gap 27 peptide would be expected to inhibit
junctions constructed of Cx32, Cx40 and Cx43, since the
second extracellular loop of each these connexin isofor-
ms contains the crucial conserved sequence SRPTEK
[14]. Although the exact mechanism of action of heptanol
is unknown [15,16], we chose to compare the functional
effects of the Gap 27 peptide with those of heptanol.
Materials and Methods
Osteoclast isolation and culture
The procedure for the isolation and culture of osteoclasts
described earlier by Boyde et al. and by Chambers et
al.[17,18] was slightly modified and has been described
in detail previously [19]. Briefly, mechanically harvested
osteoclasts from the long bones of 1 or 2-day-old
Sprague-Dawley rat pups were allowed to attach to soni-
cated bovine cortical bone slices (0.5 cm2). After 30 min-
utes, the non-attached cells were rinsed away, and the
remaining cells on the bone slices were cultured in three
groups: control, heptanol and Gap 27, described below.
Each treatment group had five bone slices and each of
the experiments was repeated three times with similar
results obtained each time. The control group was cul-
tured in DMEM (Dulbecco's modified Eagle's medium)
buffered with 20 mM Hepes and containing 0.84 g of so-
dium bicarbonate/liter, 2 mM L-glutamine, 100 IU of
penicillin/ml, 100 µg of streptomycin/ml and 7% heat-
inactivated fetal calf serum (FCS), at +37°C (5% CO
2
,
95% air), which medium will be later referred to as
DMEM-FCS. The heptanol group was cultured in medi-
um with 0.15% ethanol and 3 mM heptanol in DMEM-
FCS. We chose not to repeat our earlier experiments with
ethanol in this study, since our previous report shows
that ethanol has no effect on the parameters studied here
[12]. Third group of bone cells, Gap 27 peptide group,
was cultured with Gap 27 peptide at concentration 500
µM in DMEM-FCS. In all the three groups cells were cul-
tured for 48 hours, after which the cultures were stopped
by fixing the cells and bone slices with freshly made or
refrigerated 3% paraformaldehyde (PFA) and 2% su-
crose in phosphate-buffered saline (PBS) for 10 minutes
at room temperature. Gap 27 peptide (amino acid se-
quence SRPTEKTIFII) was synthesised by Keck Founda-
tion Biotechnology Resource Laboratory, Yale University
School of Medicine, USA; purity was >95%.
Number and activity of osteoclasts
Bone cell cultures were cultured for 48 hours with three
different treatments (control, heptanol and Gap 27). Af-
ter the culture period, bone slices were fixed as described
earlier above. The cells were stained for tartrate-resist-
ant acid phosphatase (TRAP), a commonly accepted
marker of osteoclasts [20], using a Sigma TRAP kit (no.
386-A, Sigma Chemicals, St. Louis, MO) according to the
manufacturer's instruction. To visualise the nuclei, the
cells were incubated with the DNA-binding fluoro-
chrome Hoechst 33258 (1 mg/ml stock diluted 1:800 in
PBS, Sigma Chemical Co, St. Louis, MO) for 10 minutes
at room temperature. The numbers of mononuclear and
multinucleated TRAP-positive cells on each bone slice
were counted, using a Nikon Eclipse 600 microscope
with either a Nikon Plan Fluor 20x/0.50 or a Nikon Plan
Fluor 40x/0.75 objective and a filterset UV-2E/C (DAPI)
(Nikon, Tokio, Japan).
The same cultures were also stained for filamentous ac-
tin (F-actin), as described before [21], using tetramethyl-
rhodamine isothiocyanate (TRITC)-conjugated
phalloidin (T-PHD, Sigma Chemicals, St. Louis, MO) for
20 minutes at +37°C. The cells were studied with the
Nikon microscope with a Nikon filterset G-2E/C
(TRITC). The percentages of active osteoclasts were de-
termined by counting the number of osteoclasts with ac-
tin ring divided by the number of TRAP-positive cells,
i.e., osteoclasts.
Area Measurement of Excavated Pits
Osteoclasts were cultured on bone slices for 48 hours in
the alternative growth media, after which the resorption
pits were stained and visualised as described earlier [22].
Briefly, prior to the staining of the pits, total detachment
of the cells from the bone slices was ensured by wiping
the cellular surface of the slices with a soft brush. The
pits were stained with peroxidase-conjugated wheat
germ agglutinin-lectin (WGA; 20 µg/ml, Sigma Chemi-
cal Co., St. Louis, MO) for 20 minutes, washed with PBS,
and incubated for 15 minutes in diaminobenzidine (0.5




. Morphometric analysis of the re-
sorption pits was performed with an MCID image ana-
lyser, utilising M2 software (Imaging Research Inc.,
Brock University, Ontario, Canada).
Statistical analysis
All statistical analyses were performed by first using one-
way ANOVA test. After ANOVA indicated the groups
were significantly different, Student's t-test for inde-
pendent samples was performed utilizing computer pro-
gram Microcal Origin version 4.00 (Microcal Software
Inc., Northampton, MA).Page 2 of 6
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Inhibition of gap-junctional communication leads to the 
decrease in osteoclastic survival rate
Short synthetic connexin-mimetic peptide Gap 27 is
highly effective in interrupting co-operative cell-cell in-
teractions, such as the synchronous beating of embryon-
ic cardiomyocytes [23]. Heptanol-treated cells acted as
positive controls for gap-junctional inhibition. A signifi-
cant decrease could be seen in the number of both TRAP-
positive mononuclear and multinucleated cells with Gap
27 compared to controls. We could see no difference in
the number of other cell types present in the Gap 27
treated bone cell culture. When comparing the results
from both heptanol-treated and Gap 27-treated groups,
we noticed that the numbers of TRAP-positive mononu-
clear and multinucleated cells with both treatments were
very similar (Fig. 1A and 1B).
The survival rate of osteoclasts was determined by as-
suming that the number of TRAP-positive cells in each of
the treatment groups was identical in the beginning of
the culture. After the 48-hour incubation, the amounts of
heptanol or Gap 27 – treated TRAP-positive cells were
compared to the number of TRAP-positive cells in the
control slices. Survival of osteoclasts was clearly reduced
in the groups where gap-junctional communication was
blocked either by heptanol or Gap 27 (Fig. 1C). The over-
all appearance of the cultures was changed when either
of the inhibitors were used (Fig. 2A,B,C,D,E,F).
The proportion of mononuclear TRAP-positive cells is in-
creased when gap-junctional communication is blocked
The ratio of mononuclear to multinucleated TRAP-posi-
tive cells was altered in Gap 27-treated cells compared to
controls. The control cultures contained approximately
twice the number of mononuclear TRAP-positive cells
than multinucleated TRAP-positive cells, whereas in Gap
27-treated cultures the number of mononuclear TRAP-
positive cells was three times greater than that of multi-
nucleated TRAP-positive cells. The results of the Gap 27-
treated bone cells were almost identical with heptanol-
treated bone cells (Fig. 3).
Gap-junctional communication is required for the activity 
of osteoclasts
To reveal whether Gap 27 has an effect on the activity of
the remaining osteoclasts, we counted how many of the
TRAP-positive cells of all TRAP-positive cells had actin
rings, which is commonly considered as the sign of oste-
oclastic activity. The percentage of active osteoclasts in
the Gap 27-treated cultures was dramatically decreased
when compared to control osteoclasts. Heptanol-treated
group also showed marked decrease when compared to
controls (Fig. 4A).
To further prove that gap junctions play an important
role in osteoclastic activity, we studied the effect of the
peptide on the ability of osteoclasts to form resorption
pits. A highly significant decrease could be seen in the
number of resorption pits in the Gap 27 – treated cul-
tures compared to the controls (Fig. 4B). In addition, the
total resorbed area was greatly decreased with the inhib-
itor (Fig. 4C).
Figure 1
Gap 27 decreases osteoclastic survival.(A) The num-
bers of mononuclear and (B) multinucleated TRAP-positive
cells are both decreased with Gap 27 – treatment. (C) The
survival rate of osteoclasts also decreases when gap-junc-
tional communication is blocked. Values are the means of
three independent experiments. Data are expressed as
means ± SEM and n = 5, representing the numbers of bone
slices in each study group. *p < 0.05, **p < 0.01 and ***p <
0.001, relative to control.Page 3 of 6
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We have demonstrated earlier that osteoclasts show
Cx43 staining localising over the basolateral membrane
of osteoclasts and in cell-cell contacts with mononuclear
bone marrow-derived cells [12]. It has been shown that
cells lacking morphologically and physiologically recog-
nisable gap junctions can still express Cx43 [24]. This il-
lustrates that connexin synthesis cannot automatically
be taken as proof that a cell possesses functioning inter-
cellular channels if it expresses connexin. Nevertheless,
we have also shown that inhibition of gap-junctional
communication with a commonly used gap-junctional
inhibitor heptanol causes osteoclastic apoptosis and
hence a decrease in the bone resorption [12].
In this study we have demonstrated that Gap 27 peptide
decreases osteoclastic survival rate. We suggest that the
decrease be not due to toxicity of Gap 27 to the cells,
since similar concentrations of the peptide have been
used in several studies without toxic effects [13,25,26].
In addition, number of TRAP-negative cells in these cul-
tures were unchanged and there was no evidence of ap-
optosis in this population as can be seen from Fig. 2. The
decrease in the cell number seems to be specific to oste-
oclasts, since only the number of TRAP-positive cells is
affected by the inhibitors. We can not calculate the apop-
tosis rate of these cultures, since most of the osteoclasts
have already disappeared from the heptanol and Gap 27
– treated bone slices in the 48-hour model. As we would
calculate apoptotic cells, we would actually miss those
apoptotic osteoclasts that have already been detached or
processed from the bone slices and thus, we would get in-
correct number for the apoptosis rate. Nevertheless, the
survival rate describes the survival of osteoclasts when
gap-junctional communication has been blocked.
The survival of both mononuclear and multinucleated
osteoclasts is decreased when gap-junctional communi-
cation is blocked by either of the inhibitors, but it seems
that the proportion of mononuclear TRAP-positive cells
is increased in these cultures. In the absence of gap-junc-
tional communication the multinucleated osteoclasts
seem to be more prone to die than the mononuclear
TRAP-positive precursors. The proportionally greater
number of mononuclear TRAP-positive cells could indi-
cate that gap junctions, in part, might be involved in the
fusion of mononuclear precursors into multinucleated
mature osteoclasts. The decrease in the number of
TRAP-positive multinucleated cells could thus be due to
disturbed differentiation or proliferation rates of these
cells. Osteoclasts belong to the monocyte-macrophage
cell lineage and, intriguingly, gap junctions have been
shown between macrophages during the progression of
Figure 2
Cultures stained with TRAP stain and DNA-binding
fluorochrome Hoechst 33258. The appearance of the
cultures is dramatically changed when gap-junctional commu-
nication is blocked by either of the inhibitors. (A, B) Con-
trol cultures stained with TRAP-stain and Hoechst 33258
with numerous healthy-looking TRAP-positive cells with
intact nuclei. (C, D) Heptanol-treated cultures as well as (E,
F) Gap 27 – treated cultures have fewer TRAP-positive cells.
Image width in figures 2A, C and 2E is 400 µm and in figures
2B, 2D and 2F 200 µm.
Figure 3
Gap 27 changes the ratio of mononuclear and multi-
nucleated osteoclasts. The proportional number of
mononuclear TRAP+ cells is increased in cultures where gap-
junctional communication is blocked. *p < 0.05, **p < 0.01
and ***p < 0.001, relative to control.Page 4 of 6
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also suggested the involvement of gap junctions in the
fusion of osteoclast precursors to mature osteoclasts.
However, we cannot exclude the possibility that the
greater decrease of TRAP-positive multinucleated could
also be due to detachment of the multinucleated osteo-
clasts from the substrate.
The activity of osteoclasts drops dramatically with Gap
27-treatment. This can be seen as a decrease in the per-
centage of osteoclasts with actin rings, which is recur-
rently used as a marker of osteoclastic activity.
Interestingly, Gap 27 seemed to act as even more potent
inhibitor of the activity than heptanol. The reduced activ-
ity of the remaining osteoclasts might suggest that even
though some TRAP-positive mononuclear and multinu-
cleated cells are found after Gap 27-treatment in these
cultures, they may already be undergoing some changes
leading eventually to apoptosis and thus inactivating the
cells. In addition, the resorbed area together with the
number of resorption pits decreases in these cultures
thus indicating a decreased activity of osteoclasts.
Conclusions
In summary, the present data further supports our earli-
er finding that osteoclasts have functional gap junctions,
which are important for osteoclastic function and surviv-
al. We believe, that during bone remodelling, cell con-
tacts and junctions play an important role in modulating
osteoblast and osteoclast activity, recruiting osteoblasts
that transform into osteocytes and forming an open ca-
nalicular network among osteocytes. We also believe that
the numerous diverse interactions of the bone-specific
cells described in the literature contribute to the complex
regulation of the bone remodelling [28,29]. On the basis
of these results, we conclude, that gap-junctional com-
munication is necessary for proper bone remodelling,
not only among osteoblasts, between osteoblasts and os-
teocytes but also between osteoclasts and the mononu-
clear cells of the bone marrow.
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